|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/hydrolase inhibitor
|
 |
|
Title:
|
 |
West nile virus ns2b/ns3protease in complex with bz-nle-lys-arg-arg-h
|
|
Structure:
|
 |
Genome polyprotein. Chain: a. Fragment: ns2b. Ec: 3.4.21.91,3.6.1.15,3.6.4.13,2.1.1.56,2.1.1.57,2.7.7.48. Engineered: yes. Genome polyprotein. Chain: b. Fragment: ns3pro. Ec: 3.4.21.91,3.6.1.15,3.6.4.13,2.1.1.56,2.1.1.57,2.7.7.48.
|
|
Source:
|
 |
West nile virus. Wnv. Organism_taxid: 11082. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008. Synthetic: yes. Synthetic construct. Organism_taxid: 32630
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
1.68Å
|
R-factor:
|
0.182
|
R-free:
|
0.219
|
|
|
Authors:
|
 |
N.Schiering,A.D'Arcy,P.Erbel
|
Key ref:
|
 |
P.Erbel
et al.
(2006).
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
Nat Struct Mol Biol,
13,
372-373.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
16-Jan-06
|
Release date:
|
07-Mar-06
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B:
E.C.2.1.1.56
- mRNA (guanine-N(7))-methyltransferase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L- methionine = a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L-homocysteine
|
 |
 |
 |
 |
 |
5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA
|
+
|
S-adenosyl-L- methionine
|
=
|
5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA
|
+
|
S-adenosyl-L-homocysteine
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains A, B:
E.C.2.1.1.57
- methyltransferase cap1.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-triphosphoguanosine)- (2'-O-methyl-ribonucleoside) in mRNA + S-adenosyl-L-homocysteine + H+
|
 |
 |
 |
 |
 |
5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside in mRNA
|
+
|
S-adenosyl-L-methionine
|
=
|
5'-end (N(7)-methyl 5'-triphosphoguanosine)- (2'-O-methyl-ribonucleoside) in mRNA
|
+
|
S-adenosyl-L-homocysteine
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chains A, B:
E.C.2.7.7.48
- RNA-directed Rna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
RNA(n)
|
+
|
ribonucleoside 5'-triphosphate
|
=
|
RNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chains A, B:
E.C.3.4.21.91
- flavivirin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Selective hydrolysis of Xaa-Xaa-|-Xbb bonds in which each of the Xaa can be either Arg or Lys and Xbb can be either Ser or Ala.
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
Chains A, B:
E.C.3.6.1.15
- nucleoside-triphosphate phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a ribonucleoside 5'-triphosphate + H2O = a ribonucleoside 5'-diphosphate + phosphate + H+
|
 |
 |
 |
 |
 |
ribonucleoside 5'-triphosphate
|
+
|
H2O
|
=
|
ribonucleoside 5'-diphosphate
|
+
|
phosphate
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 6:
|
 |
Chains A, B:
E.C.3.6.4.13
- Rna helicase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + H2O = ADP + phosphate + H+
|
 |
 |
 |
 |
 |
ATP
|
+
|
H2O
|
=
|
ADP
|
+
|
phosphate
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nat Struct Mol Biol
13:372-373
(2006)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
|
|
P.Erbel,
N.Schiering,
A.D'Arcy,
M.Renatus,
M.Kroemer,
S.P.Lim,
Z.Yin,
T.H.Keller,
S.G.Vasudevan,
U.Hommel.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The replication of flaviviruses requires the correct processing of their
polyprotein by the viral NS3 protease (NS3pro). Essential for the activation of
NS3pro is a 47-residue region of NS2B. Here we report the crystal structures of
a dengue NS2B-NS3pro complex and a West Nile virus NS2B-NS3pro complex with a
substrate-based inhibitor. These structures identify key residues for NS3pro
substrate recognition and clarify the mechanism of NS3pro activation.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Structures of NS2B–NS3pro in the absence and
presence of an inhibitor. (a) DEN NS2B–NS3pro. Gray,
NS3pro; yellow, NS2B. No electron density was observed for NS2B
residues 77–84. (b) WNV NS2B–NS3pro in complex with
Bz-Nle-Lys-Arg-Arg-H (orange). Residue numbering is according to
Supplementary Figure 2. Figures were made in PyMOL
(http://pymol.sourceforge.net/).
|
 |
Figure 2.
Figure 2. Stereo view of the substrate-binding region of WNV
NS2B–NS3pro, colored as in Figure 1. Potential hydrogen
bonds are indicated (dotted lines).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Mol Biol
(2006,
13,
372-373)
copyright 2006.
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
I.N.Ugwumba,
K.Ozawa,
L.de la Cruz,
Z.Q.Xu,
A.J.Herlt,
K.S.Hadler,
C.Coppin,
S.E.Brown,
G.Schenk,
J.G.Oakeshott,
and
G.Otting
(2011).
Using a genetically encoded fluorescent amino acid as a site-specific probe to detect binding of low-molecular-weight compounds.
|
| |
Assay Drug Dev Technol,
9,
50-57.
|
 |
|
|
|
|
 |
M.Y.Kondo,
L.C.Oliveira,
D.N.Okamoto,
M.R.de Araujo,
C.N.Duarte dos Santos,
M.A.Juliano,
L.Juliano,
and
I.E.Gouvea
(2011).
Yellow fever virus NS2B/NS3 protease: hydrolytic properties and substrate specificity.
|
| |
Biochem Biophys Res Commun,
407,
640-644.
|
 |
|
|
|
|
 |
S.A.Shiryaev,
A.V.Cheltsov,
K.Gawlik,
B.I.Ratnikov,
and
A.Y.Strongin
(2011).
Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase.
|
| |
Assay Drug Dev Technol,
9,
69-78.
|
 |
|
|
|
|
 |
S.A.Shiryaev,
A.V.Chernov,
T.N.Shiryaeva,
A.E.Aleshin,
and
A.Y.Strongin
(2011).
The acidic sequence of the NS4A cofactor regulates ATP hydrolysis by the HCV NS3 helicase.
|
| |
Arch Virol,
156,
313-318.
|
 |
|
|
|
|
 |
T.Knehans,
A.Schüller,
D.N.Doan,
K.Nacro,
J.Hill,
P.Güntert,
M.S.Madhusudhan,
T.Weil,
and
S.G.Vasudevan
(2011).
Structure-guided fragment-based in silico drug design of dengue protease inhibitors.
|
| |
J Comput Aided Mol Des,
25,
263-274.
|
 |
|
|
|
|
 |
J.Faver,
and
K.M.Merz
(2010).
The Utility of the HSAB Principle via the Fukui Function in Biological Systems.
|
| |
J Chem Theory Comput,
6,
548-559.
|
 |
|
|
|
|
 |
S.A.Shiryaev,
and
A.Y.Strongin
(2010).
Structural and functional parameters of the flaviviral protease: a promising antiviral drug target.
|
| |
Future Virol,
5,
593-606.
|
 |
|
|
|
|
 |
S.A.Shiryaev,
I.A.Radichev,
B.I.Ratnikov,
A.E.Aleshin,
K.Gawlik,
B.Stec,
C.Frisch,
A.Knappik,
and
A.Y.Strongin
(2010).
Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B-NS3 proteinase of West Nile virus.
|
| |
Biochem J,
427,
369-376.
|
 |
|
|
|
|
 |
S.Chandramouli,
J.S.Joseph,
S.Daudenarde,
J.Gatchalian,
C.Cornillez-Ty,
and
P.Kuhn
(2010).
Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family.
|
| |
J Virol,
84,
3059-3067.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
V.Frecer,
and
S.Miertus
(2010).
Design, structure-based focusing and in silico screening of combinatorial library of peptidomimetic inhibitors of Dengue virus NS2B-NS3 protease.
|
| |
J Comput Aided Mol Des,
24,
195-212.
|
 |
|
|
|
|
 |
W.Salaemae,
M.Junaid,
C.Angsuthanasombat,
and
G.Katzenmeier
(2010).
Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3.
|
| |
J Biomed Sci,
17,
68.
|
 |
|
|
|
|
 |
A.Sampath,
and
R.Padmanabhan
(2009).
Molecular targets for flavivirus drug discovery.
|
| |
Antiviral Res,
81,
6.
|
 |
|
|
|
|
 |
B.J.Geiss,
H.Stahla,
A.M.Hannah,
H.H.Gari,
and
S.M.Keenan
(2009).
Focus on flaviviruses: current and future drug targets.
|
| |
Future Med Chem,
1,
327.
|
 |
|
|
|
|
 |
D.Ekonomiuk,
and
A.Caflisch
(2009).
Activation of the West Nile virus NS3 protease: molecular dynamics evidence for a conformational selection mechanism.
|
| |
Protein Sci,
18,
1003-1011.
|
 |
|
|
|
|
 |
D.Ekonomiuk,
X.C.Su,
K.Ozawa,
C.Bodenreider,
S.P.Lim,
Z.Yin,
T.H.Keller,
D.Beer,
V.Patel,
G.Otting,
A.Caflisch,
and
D.Huang
(2009).
Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking.
|
| |
PLoS Negl Trop Dis,
3,
e356.
|
 |
|
|
|
|
 |
Q.Y.Koo,
A.M.Khan,
K.O.Jung,
S.Ramdas,
O.Miotto,
T.W.Tan,
V.Brusic,
J.Salmon,
and
J.T.August
(2009).
Conservation and variability of West Nile virus proteins.
|
| |
PLoS ONE,
4,
e5352.
|
 |
|
|
|
|
 |
R.Assenberg,
E.Mastrangelo,
T.S.Walter,
A.Verma,
M.Milani,
R.J.Owens,
D.I.Stuart,
J.M.Grimes,
and
E.J.Mancini
(2009).
Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication.
|
| |
J Virol,
83,
12895-12906.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.A.Shiryaev,
A.V.Chernov,
A.E.Aleshin,
T.N.Shiryaeva,
and
A.Y.Strongin
(2009).
NS4A regulates the ATPase activity of the NS3 helicase: a novel cofactor role of the non-structural protein NS4A from West Nile virus.
|
| |
J Gen Virol,
90,
2081-2085.
|
 |
|
|
|
|
 |
S.M.Tomlinson,
R.D.Malmstrom,
A.Russo,
N.Mueller,
Y.P.Pang,
and
S.J.Watowich
(2009).
Structure-based discovery of dengue virus protease inhibitors.
|
| |
Antiviral Res,
82,
110-114.
|
 |
|
|
|
|
 |
X.C.Su,
K.Ozawa,
H.Yagi,
S.P.Lim,
D.Wen,
D.Ekonomiuk,
D.Huang,
T.H.Keller,
S.Sonntag,
A.Caflisch,
S.G.Vasudevan,
and
G.Otting
(2009).
NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease.
|
| |
FEBS J,
276,
4244-4255.
|
 |
|
|
|
|
 |
X.C.Su,
K.Ozawa,
R.Qi,
S.G.Vasudevan,
S.P.Lim,
and
G.Otting
(2009).
NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease.
|
| |
PLoS Negl Trop Dis,
3,
e561.
|
 |
|
|
|
|
 |
X.Jia,
K.Ozawa,
K.Loscha,
and
G.Otting
(2009).
Glutarate and N-acetyl-L-glutamate buffers for cell-free synthesis of selectively 15N-labelled proteins.
|
| |
J Biomol NMR,
44,
59-67.
|
 |
|
|
|
|
 |
Z.Zuo,
O.W.Liew,
G.Chen,
P.C.Chong,
S.H.Lee,
K.Chen,
H.Jiang,
C.M.Puah,
and
W.Zhu
(2009).
Mechanism of NS2B-mediated activation of NS3pro in dengue virus: molecular dynamics simulations and bioassays.
|
| |
J Virol,
83,
1060-1070.
|
 |
|
|
|
|
 |
A.V.Chernov,
S.A.Shiryaev,
A.E.Aleshin,
B.I.Ratnikov,
J.W.Smith,
R.C.Liddington,
and
A.Y.Strongin
(2008).
The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase.
|
| |
J Biol Chem,
283,
17270-17278.
|
 |
|
|
|
|
 |
C.G.Patkar,
and
R.J.Kuhn
(2008).
Yellow Fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions.
|
| |
J Virol,
82,
3342-3352.
|
 |
|
|
|
|
 |
D.Luo,
T.Xu,
C.Hunke,
G.Grüber,
S.G.Vasudevan,
and
J.Lescar
(2008).
Crystal structure of the NS3 protease-helicase from dengue virus.
|
| |
J Virol,
82,
173-183.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.J.Chappell,
M.J.Stoermer,
D.P.Fairlie,
and
P.R.Young
(2008).
Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity.
|
| |
J Gen Virol,
89,
1010-1014.
|
 |
|
|
|
|
 |
N.H.Mueller,
N.Pattabiraman,
C.Ansarah-Sobrinho,
P.Viswanathan,
T.C.Pierson,
and
R.Padmanabhan
(2008).
Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen.
|
| |
Antimicrob Agents Chemother,
52,
3385-3393.
|
 |
|
|
|
|
 |
R.Perera,
and
R.J.Kuhn
(2008).
Structural proteomics of dengue virus.
|
| |
Curr Opin Microbiol,
11,
369-377.
|
 |
|
|
|
|
 |
R.Qi,
L.Zhang,
and
C.W.Chi
(2008).
Biological characteristics of dengue virus and potential targets for drug design.
|
| |
Acta Biochim Biophys Sin (Shanghai),
40,
91.
|
 |
|
|
|
|
 |
S.Schrauf,
P.Schlick,
T.Skern,
and
C.W.Mandl
(2008).
Functional analysis of potential carboxy-terminal cleavage sites of tick-borne encephalitis virus capsid protein.
|
| |
J Virol,
82,
2218-2229.
|
 |
|
|
|
|
 |
A.E.Aleshin,
S.A.Shiryaev,
A.Y.Strongin,
and
R.C.Liddington
(2007).
Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold.
|
| |
Protein Sci,
16,
795-806.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.K.Bera,
R.J.Kuhn,
and
J.L.Smith
(2007).
Functional characterization of cis and trans activity of the Flavivirus NS2B-NS3 protease.
|
| |
J Biol Chem,
282,
12883-12892.
|
 |
|
|
|
|
 |
B.D.Lindenbach,
B.M.Prágai,
R.Montserret,
R.K.Beran,
A.M.Pyle,
F.Penin,
and
C.M.Rice
(2007).
The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication.
|
| |
J Virol,
81,
8905-8918.
|
 |
|
|
|
|
 |
I.Botos,
and
A.Wlodawer
(2007).
The expanding diversity of serine hydrolases.
|
| |
Curr Opin Struct Biol,
17,
683-690.
|
 |
|
|
|
|
 |
P.A.Johnston,
J.Phillips,
T.Y.Shun,
S.Shinde,
J.S.Lazo,
D.M.Huryn,
M.C.Myers,
B.I.Ratnikov,
J.W.Smith,
Y.Su,
R.Dahl,
N.D.Cosford,
S.A.Shiryaev,
and
A.Y.Strongin
(2007).
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.
|
| |
Assay Drug Dev Technol,
5,
737-750.
|
 |
|
|
|
|
 |
S.A.Shiryaev,
A.E.Aleshin,
B.I.Ratnikov,
J.W.Smith,
R.C.Liddington,
and
A.Y.Strongin
(2007).
Expression and purification of a two-component flaviviral proteinase resistant to autocleavage at the NS2B-NS3 junction region.
|
| |
Protein Expr Purif,
52,
334-339.
|
 |
|
|
|
|
 |
S.A.Shiryaev,
B.I.Ratnikov,
A.E.Aleshin,
I.A.Kozlov,
N.A.Nelson,
M.Lebl,
J.W.Smith,
R.C.Liddington,
and
A.Y.Strongin
(2007).
Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis.
|
| |
J Virol,
81,
4501-4509.
|
 |
|
|
|
|
 |
S.Melino,
and
M.Paci
(2007).
Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
|
| |
FEBS J,
274,
2986-3002.
|
 |
|
|
|
|
 |
T.L.Yap,
T.Xu,
Y.L.Chen,
H.Malet,
M.P.Egloff,
B.Canard,
S.G.Vasudevan,
and
J.Lescar
(2007).
Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution.
|
| |
J Virol,
81,
4753-4765.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.J.Chappell,
M.J.Stoermer,
D.P.Fairlie,
and
P.R.Young
(2006).
Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies.
|
| |
J Biol Chem,
281,
38448-38458.
|
 |
|
|
|
|
 |
P.R.Mittl,
and
M.G.Grütter
(2006).
Opportunities for structure-based design of protease-directed drugs.
|
| |
Curr Opin Struct Biol,
16,
769-775.
|
 |
|
|
|
|
 |
T.H.Keller,
A.Pichota,
and
Z.Yin
(2006).
A practical view of 'druggability'.
|
| |
Curr Opin Chem Biol,
10,
357-361.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |